

# Benjamin A Teply

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5920828/benjamin-a-teply-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42  
papers

4,001  
citations

15  
h-index

44  
g-index

44  
ext. papers

4,453  
ext. citations

6.3  
avg, IF

4.76  
L-index

#	Paper	IF	Citations
42	Targeting treatment options for castration-resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , <b>2021</b> , 9, 101-120	1.6	4
41	Biomarkers for Treatment Response in Advanced Prostate Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
40	Can patients with advanced malignancy and poor performance status benefit from nivolumab plus ipilimumab as a palliative treatment?. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 12028-12028	2.2	
39	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. <i>Bone Research</i> , <b>2021</b> , 9, 24	13.3	2
38	A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4507-4507	2.2	1
37	Current Management of Refractory Germ Cell Tumors. <i>Current Oncology Reports</i> , <b>2021</b> , 23, 101	6.3	
36	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , <b>2021</b> , 79, 692-699	10.2	17
35	Navigating an Optimal Treatment Course for Advanced Kidney Cancer. <i>Oncology</i> , <b>2021</b> , 35, 308-309	1.8	
34	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 134-143	7.3	71
33	Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 10600280211033938	2.9	4
32	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1536-1543	13.4	5
31	Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors. <i>JCO Oncology Practice</i> , <b>2021</b> , OP2001055	2.3	3
30	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2486-2496	2.2	10
29	Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities. <i>Medicine (United States)</i> , <b>2021</b> , 100, e28199	1.8	0
28	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2020</b> , 1874, 188383	11.2	9
27	Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 12028-12028	2.2	5
26	Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS254-TPS254	2.2	4

25	RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC) A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5576-5576	2.2	0
24	Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 791-792	2.3	
23	Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5720-5734	12.9	15
22	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. <i>Prostate</i> , <b>2019</b> , 79, 929-933	4.2	0
21	Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS386-TPS386	2.2	1
20	Visceral metastases on abiraterone vs. placebo: A post-hoc analysis of mode of radiographic progression in COU-AA-302.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 194-194	2.2	
19	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 76-86	21.7	100
18	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 889-898	3.8	21
17	Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 499	10.2	19
16	Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16539-e16539	3.2	1
15	Chemotherapy options in castration-resistant prostate cancer. <i>Indian Journal of Urology</i> , <b>2016</b> , 32, 262-270	3.8	16
14	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2016</b> , 23, 279-90	4	10
13	Systemic therapy for bladder cancer - a medical oncologist's perspective. <i>Journal of Solid Tumors</i> , <b>2014</b> , 4, 25-35	0.3	12
12	Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. <i>ACS Nano</i> , <b>2012</b> , 6, 696-704	16.7	136
11	Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser. <i>Lasers in Medical Science</i> , <b>2012</b> , 27, 1099-102	3.1	13
10	Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy <b>2011</b> , 1263-1281		2
9	Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 2586-91	11.5	596
8	The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. <i>Biomaterials</i> , <b>2008</b> , 29, 1216-23	15.6	53

7	Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. <i>Biomaterials</i> , <b>2007</b> , 28, 869-76	15.6	1053
6	Nanoparticle-aptamer bioconjugates for targeted antineoplastic drug delivery. <i>American Journal of Drug Delivery</i> , <b>2006</b> , 4, 123-130		3
5	Collagen composite hydrogels for vocal fold lamina propria restoration. <i>Biomaterials</i> , <b>2006</b> , 27, 1104-9	15.6	108
4	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 6315-20	11.5	1448
3	Magnetically responsive polymeric microparticles for oral delivery of protein drugs. <i>Pharmaceutical Research</i> , <b>2006</b> , 23, 557-64	4.5	113
2	Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. <i>Analytical Chemistry</i> , <b>2005</b> , 77, 5453-9	7.8	145
1	Magnetite-PLGA Microparticles for Oral Delivery of Insulin. <i>Materials Research Society Symposia Proceedings</i> , <b>2005</b> , 873, 1		